Commercial Availability of Pixclara for Glioma Imaging Initiated in the U.S

Telix Pharmaceuticals has announced the U.S. commercial launch of Pixclara® (floretyrosine F 18 or 18F-FET), the first FDA-approved radiopharmaceutical imaging agent for glioma, with the first doses administered at Indiana University Health (IU Health) Neuroscience Center in Indianapolis and University Hospitals, Cleveland Medical Center.

Pixclara is designed to aid in distinguishing recurrent or progressive glioma from treatment-related changes in patients aged one month and older, both adults and pediatric patients. This innovation addresses a significant unmet need in glioma diagnostics, a pressing challenge for clinicians managing brain cancers.

Dr. Na Tosha N. Gatson, director of the Center for Neuro-Oncology at IU Health, remarked on the significant implications of this development. “Distinguishing recurrent or progressive gliomas from treatment-related change is one of the most difficult and consequential challenges in brain cancer. Having access to FDA-approved FET-PET imaging with Pixclara will help clinicians make more timely and accurate decisions,” she stated. Dr. Gatson highlighted that this would minimize diagnostic uncertainties and support more effective treatment planning.

Clement Pillainayagam, MD, from University Hospitals Cleveland Medical Center, noted the importance of Pixclara in providing a commercially available imaging option, stating that FET-PET imaging is recommended in established clinical guidelines including those from the National Comprehensive Cancer Network (NCCN). He emphasized that such availability facilitates broader access to advanced neuro-oncology care.

Kevin Richardson, CEO of Telix Precision Medicine, described the launch of Pixclara as a significant milestone for glioma patients, acknowledging the long-standing challenges in diagnosis and treatment in this area. He expressed gratitude to the various stakeholders involved in making Pixclara's availability possible.

Pixclara utilizes positron emission tomography (PET) imaging and targets the L-type amino acid transporters 1 and 2 (LAT1 and LAT2) to differentiate glioma types effectively. A Phase 3 study is underway to evaluate its potential for diagnosing brain metastases.

For safety, it is crucial to note that Pixclara may result in misinterpretations. Negative images do not exclude the possibility of glioma, and positive results should not be taken as confirmation without further clinical evaluation.

Given that gliomas account for approximately 30% of all brain tumors in the U.S. and present a significant unmet need with about 24,000 new cases diagnosed annually, the need for innovative diagnostic solutions like Pixclara is critical.